Needham analyst Ami Fadia reiterates Bicycle Therapeutics (NASDAQ:BCYC) with a Buy and maintains $72 price target.
Berkshire Hathaway Buys More Than 1.9M Additional Occidental Petroleum Shares
-Reuters Citing SEC Filing
Needham Reiterates Buy on Bicycle Therapeutics, Maintains $72 Price Target
Needham analyst Ami Fadia reiterates Bicycle Therapeutics (NASDAQ:BCYC) with a Buy and maintains $72 price target.
Related Posts
Neonode And EPICNPOC Announce Collaboration To Leverage Contactless Touch To Enhance Human-Machine Interactions
Neonode Inc. (NASDAQ:NEON) and EPICNPOC have signed a memorandum of understanding (MoU) to deliver a multimodal HMI development platform for automotive OEMs and tier-one suppliers that combines contactless touch input
Needham Reiterates Buy on Ciena, Maintains $70 Price Target
Needham analyst Alex Henderson reiterates Ciena (NYSE:CIEN) with a Buy and maintains $70 price target.
JP Morgan Assumes Bilibili at Overweight
JP Morgan analyst Daniel Chen assumes Bilibili (NASDAQ:BILI) with a Overweight rating.